<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00971282</url>
  </required_header>
  <id_info>
    <org_study_id>RD.03.SPR.29076</org_study_id>
    <nct_id>NCT00971282</nct_id>
  </id_info>
  <brief_title>Adjunctive Usage of a Moisturizing Lotion (Cetaphil® Moisturizing Lotion) to Limit the Skin Irritation Linked to the Set-Up of a Treatment by Topical Retinoid (Differin® Gel 0,1%) in Healthy Subjects of Chinese Origins</brief_title>
  <official_title>Adjunctive Usage of a Moisturizing Lotion (Cetaphil® Moisturizing Lotion) to Limit the Skin Irritation Linked to the Set-up of a Treatment by Topical Retinoid (Differin® Gel 0,1%) in Healthy Subjects of Chinese Origins</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center study, randomized, Investigator/Evaluator-blinded bilateral
      (split-face) comparison.

      The objective: To assess the benefit of the concomitant use of a Moisturizing Lotion in
      reducing the skin irritation induced by a adapalen gel treatment in Chinese Subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The interest &amp; relevance of the concomitant use of a non-comedogenic moisturizer in order to
      decrease retinoid irritation has already been demonstrated in Caucasian patients. Such
      interest of associating a moisturizer when Differin® gel is prescribed has not been
      demonstrated in Asian populations.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Erythema Rating Scale</measure>
    <time_frame>at 4 weeks</time_frame>
    <description>score from 0 (none) to 3 (severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Scaling</measure>
    <time_frame>at 4 weeks</time_frame>
    <description>score from 0 (none) to 3 (severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dryness</measure>
    <time_frame>at 4 weeks</time_frame>
    <description>score from 0 (none) to 3 (severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stinging/Burning</measure>
    <time_frame>at 4 weeks</time_frame>
    <description>score from 0 (none) to 3 (severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pruritus</measure>
    <time_frame>at 4 weeks</time_frame>
    <description>score from 0 (none) to 3 (severe)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy Skin</condition>
  <arm_group>
    <arm_group_label>intra-individual comparison</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adapalen 0.1%</intervention_name>
    <description>Intra-individual (split-face) comparison: Differin® 0.1% (whole face) will be applied once daily for 4 weeks.
Visits will be conducted weekly for a maximum of 5 visits.</description>
    <arm_group_label>intra-individual comparison</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cetaphil®</intervention_name>
    <description>Intra-individual (split-face) comparison: Cetaphil® (only one side of the face) will be applied once daily for 4 weeks.
Visits will be conducted weekly for a maximum of 5 visits.</description>
    <arm_group_label>intra-individual comparison</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female subjects of Chinese origins

          -  aged 21 years or older

          -  with healthy skin;

        Exclusion Criteria:

          -  skin pigmentation which interferes with the reading of skin reactions

          -  with sunburn, eczema, atopic dermatitis, perioral dermatitis, or rosacea on the area
             to be treated

          -  with a washout period for the following topical treatment(s) Corticosteroids, oher
             anti-inflammatory drugs, retinoids

          -  with a washout period for the following systemic treatment(s): Medications that may
             increase photosensitivity, corticosteroids, anti-inflammatories, retinoids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr LEOW</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Skin Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>national Skin Center</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2009</study_first_submitted>
  <study_first_submitted_qc>September 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2009</study_first_posted>
  <results_first_submitted>August 31, 2011</results_first_submitted>
  <results_first_submitted_qc>April 16, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 15, 2012</results_first_posted>
  <last_update_submitted>April 16, 2012</last_update_submitted>
  <last_update_submitted_qc>April 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adapalene</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intra-individual Comparison</title>
          <description>Differin applied once daily (evening) on the whole face Cetaphil applied once daily (morning) on 1 side of the face</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intra-individual Comparison</title>
          <description>Differin applied once daily (evening) on the whole face Cetaphil applied once daily (morning) on 1 side of the face</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.9" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Singapore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Erythema Rating Scale</title>
        <description>score from 0 (none) to 3 (severe)</description>
        <time_frame>at 4 weeks</time_frame>
        <population>safety population (APT)</population>
        <group_list>
          <group group_id="O1">
            <title>Cetaphil + Differin</title>
            <description>Differin applied once daily (evening) Cetaphil applied once daily (morning)</description>
          </group>
          <group group_id="O2">
            <title>Differin Alone</title>
            <description>Differin applied once daily (evening)</description>
          </group>
        </group_list>
        <measure>
          <title>Erythema Rating Scale</title>
          <description>score from 0 (none) to 3 (severe)</description>
          <population>safety population (APT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.7"/>
                    <measurement group_id="O2" value="0.7" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Scaling</title>
        <description>score from 0 (none) to 3 (severe)</description>
        <time_frame>at 4 weeks</time_frame>
        <population>safety population (APT)</population>
        <group_list>
          <group group_id="O1">
            <title>Cetaphil + Differin</title>
            <description>Differin applied once daily (evening) Cetaphil applied once daily (morning)</description>
          </group>
          <group group_id="O2">
            <title>Differin Alone</title>
            <description>Differin applied once daily (evening)</description>
          </group>
        </group_list>
        <measure>
          <title>Scaling</title>
          <description>score from 0 (none) to 3 (severe)</description>
          <population>safety population (APT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.6"/>
                    <measurement group_id="O2" value="0.6" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dryness</title>
        <description>score from 0 (none) to 3 (severe)</description>
        <time_frame>at 4 weeks</time_frame>
        <population>safety population (APT)</population>
        <group_list>
          <group group_id="O1">
            <title>Cetaphil + Differin</title>
            <description>Differin applied once daily (evening) Cetaphil applied once daily (morning)</description>
          </group>
          <group group_id="O2">
            <title>Differin Alone</title>
            <description>Differin applied once daily (evening)</description>
          </group>
        </group_list>
        <measure>
          <title>Dryness</title>
          <description>score from 0 (none) to 3 (severe)</description>
          <population>safety population (APT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.5"/>
                    <measurement group_id="O2" value="0.4" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Stinging/Burning</title>
        <description>score from 0 (none) to 3 (severe)</description>
        <time_frame>at 4 weeks</time_frame>
        <population>safety population (APT)</population>
        <group_list>
          <group group_id="O1">
            <title>Cetaphil + Differin</title>
            <description>Differin applied once daily (evening) Cetaphil applied once daily (morning)</description>
          </group>
          <group group_id="O2">
            <title>Differin Alone</title>
            <description>Differin applied once daily (evening)</description>
          </group>
        </group_list>
        <measure>
          <title>Stinging/Burning</title>
          <description>score from 0 (none) to 3 (severe)</description>
          <population>safety population (APT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.6"/>
                    <measurement group_id="O2" value="0.6" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pruritus</title>
        <description>score from 0 (none) to 3 (severe)</description>
        <time_frame>at 4 weeks</time_frame>
        <population>safety population (APT)</population>
        <group_list>
          <group group_id="O1">
            <title>Cetaphil + Differin</title>
            <description>Differin applied once daily (evening) Cetaphil applied once daily (morning)</description>
          </group>
          <group group_id="O2">
            <title>Differin Alone</title>
            <description>Differin applied once daily (evening)</description>
          </group>
        </group_list>
        <measure>
          <title>Pruritus</title>
          <description>score from 0 (none) to 3 (severe)</description>
          <population>safety population (APT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.6"/>
                    <measurement group_id="O2" value="0.6" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks</time_frame>
      <desc>All medical clinical events occurred after subject’s consent signature and during the study, whether observed by the Evaluator/Injector or reported by the Subject and whether or not thought to be treatment-related were considered adverse events and collected.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cetaphil + Differin</title>
          <description>intra-individual comparison</description>
        </group>
        <group group_id="E2">
          <title>Differin Alone</title>
          <description>intra-individual comparison</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>excoriation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>dermatitis acneiform</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>scab</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>skin exfoliation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any intent of the investigator to publish or disclose in any way the information requires the sponsor's prior written approval. The investigator shall provide their draft of such publication to sponsor for review and approval at least 2 months prior to the date of the intended publication. Sponsor shall have the absolute right to determine whether information may be published by the investigator.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Florence Paliargues</name_or_title>
      <organization>Galderma</organization>
      <phone>0033 4 92 95 29 57</phone>
      <email>Florence.Paliargues@Galderma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

